公开(公告)号：US20230382850A1

公开(公告)日：2023-11-30

申请号：US18323277

申请日：2023-05-24

Applicant: Texas Tech University System

Inventor： Nadezhda German ,  Ruwein Zhang ,  Wei Wang ,  Constantinos Mikelis ,  Luca Cucullo

IPC: C07C275/30 ,  A61K45/06

CPC classification number: C07C275/30 ,  A61K45/06

Abstract: Disclosed is a composition and method for a therapeutic treatment that is able to combat triple negative breast cancers (TNBCs). The class of urea compounds acts by blocking at inhibiting the mTOR signaling pathway, which, as a central regulator of mammalian metabolism and physiology that when inhibited leads to the induction of autophagocytosis. The disclosed compounds are further capable of reinitiating the p53 cycle as well as inhibition of the BNIP3/BNIP3L pathway. The disclosed compounds also shows the ability to cross the blood-brain-barrier where metastases can form. This new drug has the potential to be a powerful new treatment to combat invasive TNBCs.

公开(公告)号：US20200131183A1

公开(公告)日：2020-04-30

申请号：US16175540

申请日：2018-10-30

Applicant: Texas Tech University System

Inventor： Nadezhda German ,  Modammad Anwar Hossain

IPC: C07D487/04 ,  A61P25/32 ,  A61P25/36 ,  A61P25/02

Abstract: Disclosed is a composition and method for a therapeutic treatment that is able to combat certain conditions such as alcohol dependence, opioid abuse treatment, neurological disorders, neuropathic pain, and fibromyalgia. The novel gliotoxin analog compound acts by acting as an antagonist to one or more opioid receptors, which, when present leads to the inhibition of conditions, providing increased performance over known treatments. The disclosed compounds also shows the ability to cross the blood-brain-barrier in a highly efficient manner.

公开(公告)号：US11225459B2

公开(公告)日：2022-01-18

申请号：US16637695

申请日：2018-08-09

Applicant: TEXAS TECH UNIVERSITY SYSTEM

Inventor： Nadezhda German ,  Mikelis Constantinos

IPC: C07C275/30

Abstract: Disclosed is a composition and method for a therapeutic treatment that is able to combat neuroinflammation caused by diseases and disorders such as Alzheimer's disease, Parkinson's disease, and traumatic brain injury. The class of urea compounds acts by blocking at targeted receptors in the brain that contribute to the increase in inflammation. Combinations of receptors, H1 receptor, H2 receptor, dopamine transporter (DAT), and/or 5HT3C receptor, are individually and/or collectively inhibited by the same compositions of the present disclosure, and this ability leads to a decrease in brain edema. The DAT inhibitory effects additionally maintains dopamine levels in a patient.

公开(公告)号：US10787456B2

公开(公告)日：2020-09-29

申请号：US16175540

申请日：2018-10-30

Applicant: Texas Tech University System

Inventor： Nadezhda German ,  Mohammad Anwar Hossain

IPC: A61K31/407 ,  A61K31/4985 ,  C07D487/04 ,  A61P25/32 ,  A61P25/36 ,  A61P25/02

Abstract: Disclosed is a composition and method for a therapeutic treatment that is able to combat certain conditions such as alcohol dependence, opioid abuse treatment, neurological disorders, neuropathic pain, and fibromyalgia. The novel gliotoxin analog compound acts by acting as an antagonist to one or more opioid receptors, which, when present leads to the inhibition of conditions, providing increased performance over known treatments. The disclosed compounds also shows the ability to cross the blood-brain-barrier in a highly efficient manner.

公开(公告)号：US20210309607A1

公开(公告)日：2021-10-07

申请号：US17267439

申请日：2019-08-09

Applicant: Texas Tech University System

Inventor： Nadezhda German ,  Ruwein Zhang ,  Wei Wang ,  Constantinos Mikelis ,  Luca Cucullo

IPC: C07C275/30 ,  A61K45/06

Abstract: Disclosed is a composition and method for a therapeutic treatment that is able to combat triple negative breast cancers (TNBCs). The class of urea compounds acts by blocking at inhibiting the mTOR signaling pathway, which, as a central regulator of mammalian metabolism and physiology that when inhibited leads to the induction of autophagocytosis. The disclosed compounds are further capable of reinitiating the p53 cycle as well as inhibition of the BNIP3/BNIP3L pathway. The disclosed compounds also shows the ability to cross the blood-brain-barrier where metastases can form. This new drug has the potential to be a powerful new treatment to combat invasive TNBCs.

公开(公告)号：US20200181069A1

公开(公告)日：2020-06-11

申请号：US16637695

申请日：2018-08-09

Applicant: TEXAS TECH UNIVERSITY SYSTEM

Inventor： Nadezhda German ,  Mikelis Constantinos

IPC: C07C275/30

Abstract: Disclosed is a composition and method for a therapeutic treatment that is able to combat neuroinflammation caused by diseases and disorders such as Alzheimer's disease, Parkinson's disease, and traumatic brain injury. The class of urea compounds acts by blocking at targeted receptors in the brain that contribute to the increase in inflammation. Combinations of receptors, H1 receptor, H2 receptor, dopamine transporter (DAT), and/or 5HT3C receptor, are individually and/or collectively inhibited by the same compositions of the present disclosure, and this ability leads to a decrease in brain edema. The DAT inhibitory effects additionally maintains dopamine levels in a patient.